P62-zz chemical inhibitor
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsXiang-Qun Xie, Garson David Roodman, Kyaw-Zeyar Myint, Noriyoshi Kurihara
Life of this patent
Estimating the term…
Abstract
A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.
Claims26
A method for treating a p62-mediated disease in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.
A method of modulating p62 activity in stromal cells, comprising contacting stromal cells with a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of:
- wherein Ar is an arylene or heteroarylene;
- R1 has a structure of:
- wherein W is an alkanediyl, alkenediyl, a carbonyl, or a combination thereof;
- X is —NR5—, wherein R5 is H or an alkyl, or —O—;
- and
- Y is a hydroxyalkyl, an aminoalkyl, or a carboxylalkyl;
- each R2 is the same or different and has a structure of:
- wherein Z is —NR6—, wherein R6 is H or an alkyl, —O—, —S—, or —CH2—;
- Z1 is (—CH2—)m wherein m is 0 to 5, or an alkenediyl having 2 to 6 carbon atoms;
- Cy is a 3-8-membered cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring;
- and
- each R4 is the same or different and is selected from hydroxy, halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, or amino;
- and c is 0 to 5;
- and
- each R3 is the same or different and is selected from hydroxy, halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, amino, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or a nitro,
- wherein a is 2 to 5, and b is 0 to 3.
A method of inhibiting multiple myeloma cell growth, comprising contacting multiple myeloma cells with at least one p62-ZZ inhibitor compound.
A compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of:
- wherein Ar is an arylene or heteroarylene;
- R1 has a structure of:
- wherein W is an alkanediyl, alkenediyl, a carbonyl, or a combination thereof;
- X is —NR5—, wherein R5 is H or an alkyl, or —O—;
- and
- Y is a hydroxyalkyl, an aminoalkyl, or a carboxylalkyl;
- each R2 is the same or different and has a structure of:
- wherein Z is —NR6—, wherein R6 is H or an alkyl, —O—, —S—, or —CH2—;
- Z1 is (—CH2—)m wherein m is 0 to 5, or an alkenediyl having 2 to 6 carbon atoms;
- Cy is a 3-8-membered cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring;
- and
- each R4 is the same or different and is selected from hydroxy, halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, or amino;
- and c is 0 to 5;
- and
- each R3 is the same or different and is selected from hydroxy, halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, amino, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or a nitro, wherein a is 2 to 5, and b is 0 to 3.
- provided that the compound is not:
A pharmaceutical composition comprising at least one pharmaceutically acceptable additive, and a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of:
- wherein Ar is an arylene or heteroarylene;
- R1 has a structure of:
- wherein W is an alkanediyl, alkenediyl, a carbonyl, or a combination thereof;
- X is —NR5—, wherein R5 is H or an alkyl, or —O—;
- and
- Y is a hydroxyalkyl, an aminoalkyl, or a carboxylalkyl;
- each R2 is the same or different and has a structure of:
- wherein Z is —NR6—, wherein R6 is H or an alkyl, —O—, —S—, or —CH2—;
- Z1 is (—CH2—)m wherein m is 0 to 5, or an alkenediyl having 2 to 6 carbon atoms;
- Cy is a 3-8-membered cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring;
- and
- each R4 is the same or different and is selected from hydroxy, halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, or amino;
- and c is 0 to 5;
- and
- each R3 is the same or different and is selected from hydroxy, halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, amino, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or a nitro, wherein a is 2 to 5, and b is 0 to 3.
Dependencies are inferred from the claim text.